Paroxetine Hydrochloride

Paroxetine HCL CR is indicated in adults for the treatment of: Major depressive disorder (MDD) Panic disorder (PD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD) Paroxetine HCL CR is a selective serotonin reuptake inhibitor (SSRI) indicated in adults for the treatment of ( 1 ): Major Depressive Disorder (MDD) Panic Disorder (PD) Social Anxiety Disorder (SAD) Premenstrual Dysphoric Disorder (PMDD)

12.1 Mechanism of Action The mechanism of action of paroxetine in the treatment of major depressive disorder (MDD), panic disorder (PD), social anxiety disorder (SAD), and premenstrual dysphoric disorder (PMDD) is unknown, but is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-HT).

Clinical clearance of Paroxetine Hydrochloride (Serotonin Reuptake Inhibitor) relies on cytochrome cyp2d6 biotransformation with dual hepatorenal elimination with a Elimination kinetics span 5 to 12 hours per Paroxetine Hydrochloride clinical pharmacology half-life; patients absorbing at Consistent 66%–78% gastrointestinal absorption profile for Paroxetine Hydrochloride bioavailability typically observe target onset around cmax attained 2–5 hours post-administration of paroxetine hydrochloride.

FDA clinical labeling for Paroxetine Hydrochloride restricts administration in history of severe allergic sensitivity to paroxetine hydrochloride active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2026-09-16 paroxetine hydrochloride labeling across 40 mg/1 Tablet, Film Coated, 20 mg/1 Tablet, Film Coated, 12.5 mg/1 Tablet, Film Coated, Extended Release, 37.5 mg/1 Tablet, Film Coated, Extended Release, 10 mg/5mL Suspension, with self-reported patient tracking dominated by constipation (8.2% of reports), dizziness (8% of reports), diarrhea (7.4% of reports).